A 7-year-old girl with ocular myasthenia gravis (MG) refractory to prednisolone and anticholinesterase compounds was treated with high-dose intravenous immunoglobulin (IVIg). Ocular symptoms disappeared rapidly by the administration of IVIg 300 mg/kg/day for five consecutive days. Booster infusions of IVIg at an interval of 2 weeks appeared to be effective in maintaining a remission at least as an adjunct to prednisolone. The levels of acetylcholine receptor (AchR) antibodies were not correlated with clinical improvement or aggravation. Thus, high-dose IVIg may be useful in refractory cases of MG, allowing a reduction in doses of immunosuppressive drugs
Intramuscular Immunoglobulin (IMIG) have been used for 40 years in substitution therapy for antibody...
This pilot study reports our clinical experience with IVIgs as an effective therapeutic option in tr...
Myasthenia gravis (MG) is a neuromuscular disorder leading to fluctuating muscle weakness and fatigu...
A 7-year-old girl with ocular myasthenia gravis (MG) refractory to prednisolone and anticholinestera...
SUMMARY An 8 year old girl with ocular myasthenia gravis was treated with high dose intravenous immu...
Ten children (median age, 13 years; range, 3-18 yrs) with juvenile myasthenia gravis were treated wi...
Introduction Myasthenia gravis (MG) is an antibody-mediated disease that develops in the majority of...
Background/Aim. High doses of immunoglobulin G (IVIG) have been recognized as a very important thera...
Ocular myasthenia gravis is a chronic disease generally requiring years of treatment. Treatment cons...
Though the mechanisms of action of intravenous immunoglobulins (IVIG) are not completely understood,...
Myasthenia gravis (MG) is an autoimmune disease in which antibodies are directed against the postsyn...
Immunosuppression is the mainstay of treatment for myasthenia gravis (MG). In this paper, we review ...
Myasthenia gravis (MG) is one of the best understood autoantibody-mediated disorders. The pathogenic...
Juvenile myasthenia gravis is a rare acquired disease of childhood. It is difficult to differentiate...
The prognosis of myasthenia gravis (MG) has improved dramatically due to advances in critical-care m...
Intramuscular Immunoglobulin (IMIG) have been used for 40 years in substitution therapy for antibody...
This pilot study reports our clinical experience with IVIgs as an effective therapeutic option in tr...
Myasthenia gravis (MG) is a neuromuscular disorder leading to fluctuating muscle weakness and fatigu...
A 7-year-old girl with ocular myasthenia gravis (MG) refractory to prednisolone and anticholinestera...
SUMMARY An 8 year old girl with ocular myasthenia gravis was treated with high dose intravenous immu...
Ten children (median age, 13 years; range, 3-18 yrs) with juvenile myasthenia gravis were treated wi...
Introduction Myasthenia gravis (MG) is an antibody-mediated disease that develops in the majority of...
Background/Aim. High doses of immunoglobulin G (IVIG) have been recognized as a very important thera...
Ocular myasthenia gravis is a chronic disease generally requiring years of treatment. Treatment cons...
Though the mechanisms of action of intravenous immunoglobulins (IVIG) are not completely understood,...
Myasthenia gravis (MG) is an autoimmune disease in which antibodies are directed against the postsyn...
Immunosuppression is the mainstay of treatment for myasthenia gravis (MG). In this paper, we review ...
Myasthenia gravis (MG) is one of the best understood autoantibody-mediated disorders. The pathogenic...
Juvenile myasthenia gravis is a rare acquired disease of childhood. It is difficult to differentiate...
The prognosis of myasthenia gravis (MG) has improved dramatically due to advances in critical-care m...
Intramuscular Immunoglobulin (IMIG) have been used for 40 years in substitution therapy for antibody...
This pilot study reports our clinical experience with IVIgs as an effective therapeutic option in tr...
Myasthenia gravis (MG) is a neuromuscular disorder leading to fluctuating muscle weakness and fatigu...